The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
SOHO 2023 | Real-world efficacy of tafasitamab + lenalidomide in R/R DLBCL & the importance of patient selection
Jason Westin, MD, FACP, The University of Texas MD Anderson Cancer Center, Houston, TX, talks on the role of tafasitamab plus lenalidomide as a second- and third-line therapy for patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL). Dr Westin comments on real-world data (RWD) to highlight the importance of patient selection when using this regimen. This interview took place at the Eleventh Annual Meeting of the Society of Hematologic Oncology (SOHO 2023) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
